| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
PPARα (peroxisome proliferator-activated receptor alpha). Cetaben is a PPARα-independent peroxisome proliferator. It does not act through PPARα but still induces peroxisome proliferation and has hypolipidemic effects. Cetaben is a non-fibrate, PPARα-independent peroxisome proliferator with potent hypolipidemic activity.
|
|---|---|
| ln Vitro |
HepG2 and MH1C1 cells undergo substantial micromorphological and ultrastructural alterations when exposed to cetaben (10 µM) for a whole day. Following exposure to 100 µM cetaben, cells have several Golgi regions, the majority of which break down into vesicles [2]. Significant variety in the peroxisomal population is observed in cells treated with Cetaben (10 µM; 24 hours); dumbbell- and cup-shaped peroxisomal features develop in MH1C1 cells [2].
Cetaben potently reduces the concentration of cholesterol and triglycerides. It reveals a significant rise in the activities of peroxisomal enzymes in both the liver and kidney. It is a non-fibrotic lipid-lowering compound. Cetaben effectively reduces the concentration of cholesterol and triglycerides. |
| ln Vivo |
During the course of ten days, Cetaben, at dosages ranging from 50 to 100 mg/kg body weight, significantly increased the activity of peroxisomal enzymes in the liver and kidneys; however, the highest effect was noted at a dose of 250 mg/kg [1].
Cetaben has been shown to reduce serum triglyceride and cholesterol concentrations in vivo. It induces peroxisomal enzyme activities in the liver and kidney at doses of 50-100 mg/kg body over 10 days. The maximal effect is observed at 250 mg/kg. Cetaben has been shown to reduce serum triglyceride and cholesterol concentrations in vivo. |
| Enzyme Assay |
Specific protocols for in vitro enzyme/receptor binding assays for Cetaben are not detailed. Its activity is assessed by measuring its effects on peroxisomal enzyme activities and lipid levels. Cetaben reveals a significant rise in the activities of peroxisomal enzymes in both the liver and kidney.
|
| Cell Assay |
Cellular assays for Cetaben involve treating cells with the compound and measuring peroxisomal enzyme activities and lipid metabolism. Specific protocols are not detailed. Cetaben reveals a significant rise in the activities of peroxisomal enzymes in both the liver and kidney.
|
| Animal Protocol |
Animal/Disease Models: Male Wistar rat[1] Doses: 10, 25, 50, 100, 250 and 500 mg/kg
Route of Administration: gavage; 10-day Experimental Results: At doses of 50-100 mg/kg body weight, 10 The activity of peroxisomal enzymes in the liver and kidneys increased Dramatically after days, but the maximum effect was observed at the 250 mg/kg dose. In vivo animal model protocols for Cetaben involve its administration to animals to study its effects on lipid levels and peroxisomal enzyme activities. Doses of 50-100 mg/kg over 10 days are used. Cetaben has been shown to reduce serum triglyceride and cholesterol concentrations in vivo. |
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Cetaben is not available in the provided references. As a research compound, its PK properties would need to be evaluated.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for Cetaben is not available in the provided references. As a research compound, its safety profile would need to be evaluated.
|
| References |
|
| Additional Infomation |
Cetaben is a unique, PPARα-independent peroxisome proliferator with lipid-lowering activity. Cetaben lowers serum cholesterol levels by inhibiting cholesterol biosynthesis.
Cetaben is a research compound not approved for clinical use. It is a non-fibrate hypolipidemic drug that acts as a PPARα-independent peroxisome proliferator. Cetaben (CAS#: 55986-43-1) is a non-fibrate, PPARα-independent peroxisome proliferator with potent hypolipidemic activity. |
| Molecular Formula |
C23H39NO2
|
|---|---|
| Molecular Weight |
361.56126
|
| Exact Mass |
361.298
|
| CAS # |
55986-43-1
|
| Related CAS # |
55986-43-1;64059-66-1 (Na+);
|
| PubChem CID |
47263
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
503.4±33.0 °C at 760 mmHg
|
| Flash Point |
258.3±25.4 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.521
|
| LogP |
9.68
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
26
|
| Complexity |
324
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QXWKHSSBFQDQPR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H39NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-20-24-22-18-16-21(17-19-22)23(25)26/h16-19,24H,2-15,20H2,1H3,(H,25,26)
|
| Chemical Name |
4-(hexadecylamino)benzoic acid
|
| Synonyms |
Cetaben
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~69.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.91 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7658 mL | 13.8290 mL | 27.6579 mL | |
| 5 mM | 0.5532 mL | 2.7658 mL | 5.5316 mL | |
| 10 mM | 0.2766 mL | 1.3829 mL | 2.7658 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
